Argenx Se (ARGX) Net Income towards Common Stockholders (2016 - 2026)

Argenx Se's (ARGX) quarterly Net Income towards Common Stockholders came in at $472.0 million in Q2 2026, up 92.37% YoY from $245.4 million in Q2 2025, and up 28.96% on a QoQ basis from $366.0 million in Q1 2026.

Argenx Se (ARGX) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has 11 years of Net Income towards Common Stockholders data on file, last reported at $472.0 million in Q2 2026.

  • Quarterly Net Income towards Common Stockholders rose 92.37% year-over-year to $472.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 34.01% YoY) and the FY2025 annual result came in at $1.3 billion, up 55.1% from the prior year.
  • Net Income towards Common Stockholders advanced to $472.0 million in Q2 2026, from $366.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $774.2 million in Q4 2024 to a low of -$235.0 million in Q3 2022.
  • A 5-year average of $183.8 million and a median of $134.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders slumped 313.35% — and 2025, when it jumped 744.14%.
  • Tracing ARGX's Net Income towards Common Stockholders over 5 years: stood at $38.6 million in 2022, then surged by 156.84% to $99.2 million in 2023, then jumped by 680.62% to $774.2 million in 2024, then sank by 31.16% to $532.9 million in 2025, then dropped by 11.44% to $472.0 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at $472.0 million (Q2 2026), $366.0 million (Q1 2026), and $532.9 million (Q4 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 472.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -644.37 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 237.01 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 930.12
7 Royalty Pharma 33.72 Bn 35.84 Bn - 81.49 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 164.49 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -13.27 Mn
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -290.61 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 472.00 Mn
Mar 31, 2026 366.00 Mn
Dec 31, 2025 532.95 Mn
Sep 30, 2025 344.26 Mn
Jun 30, 2025 245.36 Mn
Mar 31, 2025 169.00 Mn
Dec 31, 2024 774.16 Mn
Sep 30, 2024 91.41 Mn
Jun 30, 2024 29.07 Mn
Mar 31, 2024 -61.60 Mn
Dec 31, 2023 99.17 Mn
Sep 30, 2023 72.64 Mn
Jun 30, 2023 -94.37 Mn
Mar 31, 2023 28.87 Mn
Dec 31, 2022 38.61 Mn
Sep 30, 2022 -235.04 Mn
Jun 30, 2022 208.75 Mn
Mar 31, 2022 227.19 Mn
Dec 31, 2021 -237.82 Mn
Sep 30, 2021 -233.61 Mn